PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

NCT00407576 | Completed Phase 1

• 2 other identifiers: 07003607-M-0036
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography (PET) and a research drug called \[11C\]MeS-IMPY.

Conditions

Alzheimer's Disease; Healthy

Keywords

Alzheimer's Disease; Positron Emission Tomography; Brain; Neurochemistry; Beta-Amyloid Plaques; PET; MeS-IMPY; Alzheimer Disease; AD; Dementia; Healthy Volunteer; HV

Interventions

[11C]MeS-IMPY DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy control subjects aged 18-90 years and AD patients aged 50-90, with history/physical exam, ECG, and laboratory tests.
• Informed Consent.
• AD Patients: Mini-Mental State Examination (score greater than or equal to 10).
• AD Patients: Meet NINCDS-ADRDA criteria for probable AD.

You may not qualify if:

• Current or prior history of any alcohol or drug abuse.
• Severe systemic disease based on history and physical exam.
• Positive result on urine screen for illicit drugs.
• Laboratory tests with clinically significant abnormalities.
• Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.
• Pregnancy or breast feeding.
• Claustrophobia.
• Presence of ferromagnetic metal in the body or heart pacemaker.
• History of brain disease other than Alzheimer's disease.
• Unable to lay on one's back for the PET/MRI scan.

Sponsors & Collaborators

• National Institute of Mental Health (NIMH): lead

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

• Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, Cole GM, Small GW, Huang SC, Barrio JR. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci. 2001 Dec 15;21(24):RC189. doi: 10.1523/JNEUROSCI.21-24-j0004.2001.

  PMID: 11734604 BACKGROUND

• Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med. 1997 Nov;38(11):1818-23.

  PMID: 9374364 BACKGROUND

• Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab. 2002 Oct;22(10):1271-81. doi: 10.1097/01.WCB.0000038000.34930.4E.

  PMID: 12368666 BACKGROUND

MeSH Terms

Conditions

Alzheimer Disease; Dementia

Interventions

N,N-dimethyl-4-(6-(methylthio)imidazo(1,2-a)pyridine-2-yl)aniline

Condition Hierarchy (Ancestors)

Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Study Design

• Study Type: interventional
• Phase: phase 1
• Purpose: TREATMENT
• Sponsor Type: NIH

Study Record Dates

• First Submitted: December 2, 2006
• First Posted: December 5, 2006
• Study Start: December 1, 2006
• Primary Completion: November 7, 2008
• Last Updated: July 2, 2017

Record last verified: 2008-11-07

Locations

US (1)